Data as of Nov 4, 2026.
BIOY vs CHPY: Dividend Yield & Total Return
BIOY and CHPY both write options for income.
askIQ about this page
askIQ about BIOY and CHPY
Net assets on Nov 3, 2026: $1.5m for GraniteShares YieldBOOST Biotech ETF and $1.2bn for YieldMax Semiconductor Portfolio Option Income ETF.
13.6 pts behind XBI
BIOY since launch: paid 26.1%, price −21.9%, total +5.4%, XBI +19.0%, −13.6 pts. Data to Nov 4, 2026.
XBI
+19.0%
BIOY
+5.4%
13.6 pts behind XBI
Total return, distributions reinvested
13.6 pts behind XBI
BIOY since launch: paid 26.1%, price −21.9%, total +5.4%, XBI +19.0%, −13.6 pts. Data to Nov 4, 2026.
XBI
+19.0%
BIOY
+5.4%
13.6 pts behind XBI
26.1% of it arrived as cash. Total return, distributions reinvested. BIOY since launch: paid 26.1%, price −21.9%, total +5.4%, XBI +19.0%, −13.6 pts. Data to Nov 4, 2026.
Data to Nov 4, 2026.29.5 pts ahead of SPY
CHPY over 1 year: paid 48.9%, price −6.0%, total +44.3%, SPY +14.8%, +29.5 pts. Data to Nov 4, 2026.
SPY
+14.8%
CHPY
+44.3%
48.9% of it arrived as cash
29.5 pts ahead of SPY
Total return, distributions reinvested
29.5 pts ahead of SPY
CHPY over 1 year: paid 48.9%, price −6.0%, total +44.3%, SPY +14.8%, +29.5 pts. Data to Nov 4, 2026.
SPY
+14.8%
CHPY
+44.3%
48.9% as cash
29.5 pts ahead of SPY
48.9% of it arrived as cash. Both charts share one scale, with zero at the line. CHPY over 1 year: paid 48.9%, price −6.0%, total +44.3%, SPY +14.8%, +29.5 pts. Data to Nov 4, 2026.
Data to Nov 4, 2026.Pair scorecard
CHPY costs 0.15 points a year less; CHPY is far larger, $1.2bn against $1.5m.
Points (pts) are percentage points.
| Measure | BIOY | CHPY |
|---|---|---|
| Paid and earned | ||
| Total return, 1 year | not published | +44.3% |
| Price change | fell 21.9% (since May 5, 2026) | fell 6.0% (1 year) |
| Return of capital, issuer estimate | 96% of the Sep 22, 2026 payment | 99% of the Nov 5, 2026 payment |
| Against its benchmark | ||
| Benchmark | Biotech, measured through XBI | S&P 500, measured through SPY |
| Cost and size | ||
| Expense ratio | 1.18% | 1.03% |
| Net assets, as of Nov 3, 2026 | $1.5m | $1.2bn |
| Holdings | ||
| Holdings in common | 0% | |
Risk and return
May 15, 2026 to Oct 30, 2026 · 24 weekly returnsFrom May 2026 to Oct 2026, BIOY returned more: +4.3% to −6.1%. BIOY fell less at its worst: −5.8% to −24.4%.
Full scorecard
3 measures, with how each is measured Open ↓
| Measure | BIOY | CHPY | Edge | How it is measured |
|---|---|---|---|---|
| Return | ||||
| Total return | +4.3% | −6.1% | BIOY | Price change plus distributions, reinvested. |
| Price return | −20.9% | −22.8% | BIOY (slight) | Price change alone, distributions left out. |
| Risk | ||||
| Max drawdown | −5.8% | −24.4% | BIOY | Deepest fall from a high to the low after it. |
Computed by ETFIQ from Tiingo daily prices and ETFIQ's distribution records, 24 weekly returns. Cash rate: the 13-week Treasury bill.
What they share
By the books each fund has filed, BIOY and CHPY hold 0% of their money in the same securities at the same weight. Holdings dated Jun 30, 2026 and Nov 4, 2026.
half
0% in common
Only in one fund ↓
Side by side
As of Nov 4, 2026. Source: ETFIQ. Cash paid: distributions over the window, as a share of the starting price. Payout rate: the latest payment, annualized, over today’s price.
Window by window
| Total return | Cash paid | Against the benchmark | ||||
|---|---|---|---|---|---|---|
| Window | BIOY | CHPY | BIOY | CHPY | BIOY | CHPY |
| 3 months | +6.9% | −14.2% | 14.5% | 9.9% | +2.9 pts | −14.1 pts |
| 6 months | +4.4% | −9.7% | 25.9% | 20.6% | −11.3 pts | −14.7 pts |
| 1 year | – | +44.3% | – | 48.9% | – | +29.5 pts |
| Since launchNot the same days: BIOY May 2026 · CHPY Apr 2025 | +5.4% | +126.5% | 26.1% | 87.4% | −13.7 pts | +81.2 pts |
– means no data for this window. Open this comparison in the app →
No client brief for this pair: ETFIQ prints no one-year total return for BIOY; the two funds' holdings are dated 127 days apart.
BIOY
Over the period from its first trade on May 5, 2026 to Nov 4, 2026, BIOY paid 26.1% of its starting value in cash distributions while its price fell 21.9%. With every distribution reinvested, the fund returned +5.4%. Biotech (XBI) returned +19.0% over the same days, so a holder was behind by 13.6 pts. At its price on Nov 4, 2026 the latest distribution annualizes to 60.7%, paid weekly. GraniteShares estimates that 96% of the distribution paid Sep 22, 2026 was a return of capital (its 19a-1 notice). That is a tax label, not a measure of erosion.
CHPY
Over the year to Nov 4, 2026, CHPY paid 48.9% of its starting value in cash distributions while its price fell 6.0%. With every distribution reinvested, the fund returned +44.3%. S&P 500 (SPY) returned +14.8% over the same days, so a holder was ahead by 29.5 pts. At its price on Nov 4, 2026 the latest distribution annualizes to 40.7%, paid weekly. YieldMax estimates that 99% of the distribution paid Nov 5, 2026 was a return of capital (its 19a-1 notice).
Questions people ask
Links are sources, not endorsements. A comparison is not a recommendation.
How this is computed
Overlap adds up the smaller of the two weights for each security both funds hold.
Every number is an ETFIQ calculation with distributions reinvested.
Cite this pageCitation, APA and Markdown
ETFIQ, BIOY against CHPY, data as of Nov 4, 2026. https://etfiq.com/compare/income/bioy-vs-chpy
ETFIQ. (Nov 4, 2026). BIOY against CHPY. Retrieved from https://etfiq.com/compare/income/bioy-vs-chpy
[BIOY against CHPY (ETFIQ, Nov 4, 2026)](https://etfiq.com/compare/income/bioy-vs-chpy)
Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.